Cellular uptake and activity of heparin functionalised cerium oxide nanoparticles in monocytes

Biomaterials

Volumn 34, Issue 17, 2013, Pages 4377-4386

  Ting, S R Simon ^a,c   Whitelock, John M ^a   Tomic, Romana ^a   Gunawan, Cindy ^a   Teoh, Wey Yang ^b   Amal, Rose ^a   Lord, Megan S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Cerium oxide; Heparin; Macrophage; Nanoparticle; Reactive oxygen species

Indexed keywords

3-AMINOPROPYLTRIETHOXYSILANE; BIOLOGICAL PROPERTIES; CERIUM OXIDE NANOPARTICLE; CERIUM OXIDES; FIBROBLAST GROWTH FACTOR 2; FLAME SPRAY PYROLYSIS; HEPARIN; REACTIVE OXYGEN SPECIES;

BODY FLUIDS; CELL CULTURE; CELLS; MACROPHAGES; NANOPARTICLES; OXIDES; OXYGEN; SILANES; SPRAY PYROLYSIS; THERMOGRAVIMETRIC ANALYSIS;

POLYSACCHARIDES;

3 AMINOPROPYLTRIETHOXYSILANE; CERIUM OXIDE NANOPARTICLE; FIBROBLAST GROWTH FACTOR 2; HEPARIN; METAL NANOPARTICLE; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PYROLYSIS; THERMOGRAVIMETRY;

ANIMALS; CELL SURVIVAL; CERIUM; ENDOCYTOSIS; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; HEPARIN; HUMANS; MICE; MOLECULAR WEIGHT; MONOCYTES; NANOPARTICLES; OXIDATION-REDUCTION; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; SILANES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; U937 CELLS;

EID: 84875551137     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.042     Document Type: Article

References (47)

1. Kemp M.M., Linhardt R.J. Heparin-based nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:77-87.
2. Lord M.S., Jung M., Teoh W.Y., Gunawan C., Vassie J., Amal R., et al. Cellular uptake and and reactive oxygen species modulation of cerium oxide nanoparticles in human monocyte cell line U937. Biomaterials 2012, 33:7915-7924.
3. Asati A., Santra S., Kaittanis C., Perez J.M. Surface-charge-dependent cell localisation and cytotoxicity of cerium oxide nanoparticles. ACS Nano 2010, 4:5321-5331.
4. 3+ ions determine redox-dependent anti-apoptotic effect of cerium oxide nanoparticles. ACS Nano 2011, 5:4537-4549.
5. Pirmohamed T., Dowding J.M., Singh S., Wasserman B., Heckert E., Karakoti A.S., et al. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem Commun 2010, 46:2736-2738.
6. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
7. Kemp M.M., Kumar A., Mousa S., Park T.-J., Ajayan P., Kubotera N., et al. Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules 2009, 10:589-595.
8. Ornitz D.M., Yayon A., Flanagan J.G., Svahn C.M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992, 12:240-247.
9. Guimond S., Maccarana M., Olwin B.B., Lindahl U., Rapraeger A.C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). J Biol Chem 1993, 268:23906-23914.
10. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed 2002, 41:390-412.
11. Kolset S.O., Tviet H. Serglycin - structure and biology. Cell Mol Life Sci 2008, 65:1073-1085.
12. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105:2745-2764.
13. Whitelock J.M., Melrose J. Heparan sulfate proteoglycans in healthy and diseased systems. Wiley Interdiscip Rev Syst Biol Med 2011, 3:739-751.
14. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
15. Passirani C., Barratt G., Devissaguet J.-P., Labarre D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci 1998, 62:775-785.
16. Lian L., Tang T., Yang J., Liu C., Li Y. Therapeutic angiogenesis of PLGA-heparin nanoparticle in mouse ischemic limb. J Nanomater 2012, art no. 193704.
17. Jiao Y., Ubrich N., Marchand-Arvier M., Vieron C., Hoffman M., Lecompte T., et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002, 105:230-235.
18. Lee J., Jung M.J., Hwang Y.H., Lee Y.J., Lee S., Shin H. Heparin-coated superparamagnetic iron oxide for in vivo MR imaging of human MSCs. Biomaterials 2012, 33:4861-4871.
19. Wuang S.C., Neoh K.G., Kang E.-T., Pack D.W., Leckband D.E. Heparinized magnetic nanoparticles: in vitro assessment for biomedical applications. Adv Funct Mat 2006, 16:1723-1730.
20. Qi L., Fresnais J., Muller P., Theodoly O., Berret J.-F., Chapel J.-P. Interfacial activity of phosphonated-PEG functionalized cerium oxide nanoparticles. Langmuir 2012, 28:11448-11456.
21. Karakoti A.S., Singh S., Kumar A., Malinska M., Kuchibhatla S.V.N.T., Wozniak K., et al. PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc 2009, 131:14144-14145.
22. Perez J.M., Asati A., Nath S., Kaittanis C. Synthesis of biocompatible dextran-coated nanoceria with pH-dependent antioxidant properties. Small 2008, 4:552-556.
23. Cimini A., D'Angelo B., Das S., Gentile R., Benedetti E., Singh V., et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater 2012, 8:2056-2067.
24. Patil S., Sandberg A., Heckert E., Self W., Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 2007, 28:4600-4607.
25. Moseley R., Waddington R., Evans P., Halliwell B., Embery G. The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim Biophys Acta 1995, 1244:245-252.
26. Liu Z., Perlin A.S. Evidence of a selective free radical degradation of heparin, mediated by cupric ion. Carbohydr Res 1994, 255:183-191.
27. Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., C F., et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297.
28. Chuang C.Y., Lord M.S., Melrose J., Rees M.D., Knox S.M., Freeman C., et al. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49:5524-5532.
29. Minta J.O., Pambrun L. In vitro induction of cytologic and functional differentiation of the immature human monocyte-like cell line U-937 with phorbol myristate acetate. Am J Pathol 1985, 119:111-126.
30. Karakoti A.S., Singh C., Dowding J.M., Seal S., Self W. Redox-active radical scavenging nanomaterials. Chem Soc Rev 2010, 39:4422-4432.
31. Park E.-J., Choi J., Park Y.-K., Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicity 2008, 245:90-100.
32. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol 2001, 2:3005.
33. Turnbull J.E., Fernig D.G., Ke Y., Wilkinson M.C., Gallagher J.T. Identification of the basic fibroblast growth factor binding sequences in fibroblast heparan sulfate. J Biol Chem 1992, 267:10337-10341.
34. Moy F.J., Safran M., Seddon A.P., Kitchen D., Böhlen P., Aviezer D., et al. Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 1997, 36:4782-4791.
35. Li D., Teoh W.Y., Gooding J.J., Selomulya C., Amal R. Functionalization strategies for protease immobilization on magnetic nanoparticles. Adv Funct Mat 2010, 20:1767-1777.
36. Hirst S.M., Karakoti A.S., Tyler R.D., Sriranganathan N., Seal S., Reilly C.M. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009, 5:2848-2856.
37. Heckert E., Karakoti A.S., Seal S., Self W. The role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials 2008, 29:2705-2709.
38. Horie M., Nishio K., Kato H., Fujita K., Endoh S., Nakamura A., et al. Cellular responses induced by cerium oxide nanoparticles: induction of intracellular calcium level and oxidate stress on culture cells. J Biochem 2011, 150:461-471.
39. Manduteanu I., Voinea M., Antohe F., Dragomir E., Capraru M., Radulescu L., et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003, 477:269-276.
40. Dandona P., Qutob T., Hamouda W., Bakri F., Aljada A., Kumbkarni Y. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res 1999, 96:437-443.
41. Walkey C.D., Olsen J.B., Guo H., Emili A., Chan W.C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012, 134:2139-2147.
42. Wilhelm C., Billotey C., Roger J., Pons J.N., Bacri J.C., Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24:1001-1011.
43. Trindade E.S., Boucas R.I., Rocha H.A., Dominato J.A., Paredes-Gamero E.J., Franco C.R., et al. Internalization and degradation of heparin is not required for stimulus of heparan sulfate proteoglycan synthesis. J Cell Physiol 2008, 217:360-366.
44. Metcalfe D.D., Thompson H.L., Klebanoff S.J., Henderson W.R. Oxidative degradation of rat mast-cell heparin proteoglycans. Biochem J 1990, 272:51-57.
45. Vogtländer N.P., Tamboer W.P., Bakker M.A., Campbell K.P., van der Vlag J., Berden J.H. Reactive oxygen species deglycosylate glomerular α-dystroglycan. Kidney Int 2006, 69:1526-1534.
46. Nagasawa K., Uchiyama H., Sato N., Hatano A. Chemical change involved in the oxidative-reductive depolymerization of heparin. Carbohydr Res 1992, 236:165-180.
47. Raats C.J., Bakker M.A., van den Born J., Berden J.H. Hydroxyl radicals depolymerise glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997, 272:26734-26741.